Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
Yael Renert-YuvalAna B PavelEster Del DucaPaola FacherisAngel D PaganSwaroop BosePedro J Gómez-AriasMichael AngelovJennifer BaresMargo ChimaYeriel D EstradaSandra GarcetMark G LebwohlJames G KruegerEmma Guttman-YasskyPublished in: Allergy (2022)
Scalp biomarkers provide evidence of dupilumab efficacy in AA, detected even prior to clinical response, with exclusive correlations between early suppression of Th2 markers and increased hair keratins. These findings strengthen previous reports suggesting a possible role for Th2 cytokines as AA drivers.